• 소규모 펩티드 합성 시스템
큐
X
큐

MK-677 (Ibutamoren) (60 캡슐)

카테고리 :, ,

주문하려면 연락
지금 바로 이메일을 보내 1:1 지원과 함께 주문을 하세요. 한정 재고! Zelle, CashApp, Venmo, 은행 송금, 암호화폐 결제를 받습니다.
MK-677이 부타 모렌 및 오라 트로프로도 알려진 것은 그렐린 수용체의 경구 활성, 선택적 작용제이다. 연구에 따르면 MK-677은 성장 호르몬 (GH) 및 인슐린 유사 성장 인자 1 (IGF-1)의 자연 분비를 증가 시키지만 코티솔 수준에는 영향을 미치지 않습니다. 그것은 성장 호르몬 결핍, 근육 및 뼈 낭비, 식욕 자극 및 알츠하이머 병에 대한 가능한 치료법으로 연구되고 있습니다. 마우스에 대한 MK-677 연구는 상당한 아밀로이드 베타 축적 전에 시작된 한 유전자 적으로 소인 된 마우스에서도 AD의 발병을 방지하는 것으로 나타났다. MK-677 연구는 또한 수면 품질 향상에있어 매우 유망한 이점을 보여주었습니다.
제품 사용 :이 제품은 연구 화학 물질로만 의도 된 것입니다.이 명칭은 시험 관내 시험 및 실험실 실험에만 연구 화학 물질을 엄격하게 사용할 수있게한다. 이 웹 사이트에서 제공되는 모든 제품 정보는 교육 목적으로 만 사용됩니다. 인간이나 동물에 어떤 종류의 신체적으로 소개되는 것은 법에 의해 엄격히 금지되어 있습니다. 이 제품은 라이센스가 부여 된 자격을 갖춘 전문가 만 처리해야합니다. 이 제품은 약물, 음식 또는 화장품이 아니며 약물, 음식 또는 화장품으로 잘못 브랜드화되거나 잘못 사용되거나 오해가되지 않을 수 있습니다.

MK-677 (Ibutamoren) 개요

Ibutamoren 및 Oratrope로도 알려진 MK-677은 Ghrelin 수용체의 강력하고 구강 활성, 선택적 작용제입니다. 이것은 그것을 성장 호르몬 분비 대상과 그렐린 모방으로 만듭니다. 그것은~ 아니다그러나, 그렐린 유사체는 펩티드가 아니기 때문에 그렐린과 구조적 유사성을 공유하지 않기 때문이다. 연구에 따르면 MK-677은 성장 호르몬 (GH) 및 인슐린 유사 성장 인자 1 (IGF-1)의 분비를 증가 시키지만 코티솔 수준에는 영향을 미치지 않습니다. 이는 MK-677이 GH 축을 활성화시켜 마른 체질량의 증가를 촉진한다는 것을 의미합니다. 성장 호르몬 결핍, 근육 및 뼈 낭비 및 식욕 자극의 치료로 조사 중입니다. MK-677은 긴 반감기와 우수한 구강 생체 이용률로 평가됩니다. 인간의 연구에 따르면 IGF-1 수준은 단일 용량의 MK-677 후 최대 24 시간 동안 계속 증가 함을 보여줍니다.

MK-677 및 Sarms

MK-677 is often grouped with the selective androgen receptor modulators (SARMs) because it doesn’t fit neatly into any other category. MK-677 is not a SARM, however. It also isn’t a peptide. It is best described as a complex, synthetic chemical propanamide derivative that acts as a ghrelin receptor agonist[1]. Though it is not a peptide, MK-677 best fits into the growth hormone secretagogue family of peptides if considering effects. Like GHRP-2, GHRP-6, hexarelin, and ipamorelin, MK-677 binds to the ghrelin/growth hormone secretagogue receptor and boosts GH release while maintaining normal physiologic, pulsatile patterns of GH fluctuation. One of the benefits of MK-677 is actually the fact that it is not a SARM. SARMs tend to impact natural androgen production and thus can lower testosterone levels. This means that their administration must be carefully controlled and that the compounds should be cycled on and off to avoid suppression of natural androgen production. MK-677 does not require these precautions.

MK-677 구조

분자식 :기음27시간36N4영형5에스분자량 :528.7 g/molPubchem CID :9939050 CAS 번호 :159634-47-6동의어 :MK-0677, Oratrope, Ibutamoren, L-163,191Structure원천:Pubch

MK-677 연구

MK-677 및 체세포

It has been shown that without intervention, growth hormone secretion and muscle mass decline starting at mid-puberty. This ultimately leads to the frailty and loss of muscle function we see in the elderly. The progressive decline of GH and IGF-1 with age is referred to as somatopause. On average, a male at 70 years of age will produce about 60% of the growth hormone he produced at age 18. This can lead to changes in body composition, loss of bone density, and more. Interestingly, estrogen and progesterone appear to increase GH and IGF-1 levels, thereby reducing the effects of somatopause in women as they age. Compounds like MK-677 may offer a way of slowing or even halting the progression of somatopause. This could lead to improved muscle and bone strength in older age and may affect everything from cardiac function to brain health. Research is in its early stages, but a number of animal and human trials are showing early promise.

MK-677 및 체성분

If somatopause is such a substantial contributor to the frailty of aging, then reversing, preventing, or slowing it could help to stave off age-related declines in bone density, muscle strength, and more. In a 2-year randomized controlled trial complete with placebo, blinding, and crossover, researchers demonstrated that once daily oral administration of MK-677 (just 25 mg) significantly increased growth hormone levels and IGF-1 levels without serious adverse effects. This resulted in an increase in body weight of approximately 2 kg compared to placebo, increased bone mineral density, no changes in strength, and no changes in fat mass. Subjects also experienced a decrease in LDL cholesterol (bad cholesterol) and modest increases in cortisol levels. Appetite increased initially, but reverted to normal after several months[2]. One potentially interesting application of MK-677 may be in the setting of diet induced negative nitrogen balance, which is a complicated clinical way of saying low-protein consumption. Low protein consumption can be the result of a number of things, but is most often seen in the healthcare setting as a result of disease or disability. It is particularly problematic for bed-ridden patients, such as those who have suffered trauma. The ability of MK-677 to counteract negative nitrogen balance is not just about nutrition, however[3]. Protecting protein stores in the body from depletion can lead to better clinical outcomes in everything from stroke to infection. It can even help to prolong lifespan and healthspan by protecting against the disability associated with sarcopenia (muscle loss). Previous research has shown that simultaneously boosting GH and IGF-1 can improve nitrogen retention in the setting of parenteral nutrition[3]. This is precisely what MK-677 does with a single orally administered dose. This function alone may make MK-677 a staple of intensive care units in the near future. Research in elderly patients has shown that daily ibutamoren can boost the GH/IGF-1 axis to levels similar to those found in healthy young adults. This occurs without serious adverse effects and results in a significant increase in lean body mass, decreases in LDL cholesterol, and no change in HDL cholesterol[5]. There is some interest then in using ibutamoren as a long-term supplement to ward off the muscle loss and body composition changes associated with aging. Overall, MK-677 administration appears to have limited effects on body composition. Combined with exercise, however, it’s ability to increase GH and IGF-1 levels may help to improve muscle strength and density, reduce fat mass, and boost bone density. Bone density is discussed in detail in the next section.

MK-677 및 뼈 밀도

Research in young, obese males shows that MK-677 significantly alters bone function by increasing both bone deposition and resorption[6]. Similar results are seen in elderly test subjects[7]. These findings are a classic indication of increased bone remodeling and can be either good or bad depending on the setting. Increased bone remodeling can lead to improved bone strength and resistance to fracture when paired with weight/resistance training, for instance. In a multi-center study of elderly patients with hip fracture, research shows that MK-677 can improve gait speed and reduced numbers of falls[8]. These is thus reason to believe that the compound does, in fact, improve bone density and function, but more research is needed. In one trial, 9 weeks of MK-677 resulted in a nearly 30% increase in serum ostocalcin and a 10% increase in bone-specific alkaline phosphatase. Both of these markers suggest increased bone deposition[5]. Individuals in these studies showed a trend toward more independent living following hip fracture. A great deal more research needs to be done, particularly as there is reason to believe that MK-677 may be synergistic with some of the growth hormone releasing hormone (GHRH) analogues and growth hormone releasing peptides (GHRPs) like sermorelin and tesamorelin.

MK-677 및 신경 학적 기능

Research in animals has demonstrated that IGF-1 is an important component in the clearance of amyloid beta from the central nervous system. Amyloid beta plaques that result from a build-up of amyloid beta are a hallmark of Alzheimer’s disease (AD) and are indicative of disease severity. It is interesting that AD is a disease of the elderly because IGF-1 levels in the brain have been shown to decrease with age and are even lower in patients suffering from AD. The ability to raise IGF-1 levels could, therefore, provide an effective treatment or preventative for AD. Research in elderly patients has found that MK-677 increases IGF-1 levels substantially, but does not alter the progression of AD once it has been diagnosed[9]. There is interest, however, in attempting to understand whether it can prevent AD. Unfortunately, such trials take extensive amounts of time and money. Research into the ability of MK-677 to prevent AD-like neurodegeneration in animal models actually contradicts the human study just discussed. This animal research is actually much newer and suggests that MK-677, more than a curative agent, is an excellent preventative. In this research, Mice that were genetically predisposed to developed AD but that were treated with MK-677 starting at three months of age showed reduced amyloid beta deposition and resulting decreases in neuron and synapse loss. In other words, MK-677 appeared to prevent the onset of AD, even in genetically predisposed mice, as long as it was started before significant amyloid beta accumulation[10].Neurological원천:MDPI물론, 위의 발견은 비만 및 AD에 대한 연구에 의해 더욱 뒷받침됩니다. 과체중 마우스에 대한 연구에 따르면 아밀로이드 베타의 말초 제거가 손상되고 IGF-1 수준이 증가하면이 기능 장애를 개선하는 데 도움이됩니다. 불행하게도, 이것은 뇌의 아밀로이드 베타 수준에 거의 영향을 미치지 않으며, 이는 IGF-1이 혈액-뇌 장벽 (BBB)을 잘 교차하지 않는다는 것을 시사한다.

MK-677 및 수면

MK-677 has more robust effects on sleep than any of the GHRPs. Research in young adults shows that MK-677 increases stage 4 sleep duration by 50% and increase REM sleep by 20%. In older adults, the results are even more profound, with REM sleep increasing by as much as 50% and REM latency decreasing substantially[11]. Stage 4 sleep is generally considered to be the most restful stage of sleep and critical to preserving waking brain function. Stage 4 is also when most serious tissue repair and wound healing takes place. In children, it may be associated with growth and development. Prolonging this stage of sleep could be beneficial to muscle recovery, brain function, and development. REM sleep isn’t clearly understood, but we know that babies spend half their sleep time in REM and that this number declines with age. REM may be critical in the consolidation and reinforcement of memories, but no one really knows. The ability to prolong REM in animal models could make MK-677 a important tool for understanding the functions of sleep better than we ever have before.

MK-677 및 심장 건강

It has long been known that aging leads to impairment of stem cell function. Endothelial progenitor cells (EPCs) are stem cells important in the regeneration of blood vessels. A decline in EPCs has been thought to be a risk factor for the development of atherosclerosis, which can lead to high blood pressure and heart attack among other problems. Research in mice shows that increased GH levels can help to reverse the age-related decline in EPCs and may therefore be useful in preventing heart disease[12], [13]. Further supporting the importance of GH in cardiac health is that fact the nitric oxide levels decline with age. Nitric oxide (NO) is an important regulator of blood vessel health and is critical in controlling blood pressure. GH treatment has been shown to increase NO synthase expression and thus NO levels in mice.[14] This could ultimately be an effective way to regulate blood pressure and reduce risk of a number of cardiac diseases, kidney disease, and even stroke.

MK-677 요약

MK-677 is a non-peptide ghrelin/growth hormone secretagogue agonist that has been shown to raise GH and IGF-1 levels in both animal and human testing. The compound has gone through several human clinical trials and is generally considered to be safe and relatively free of side effects, though it has not yet been approved for human use outside of clinical trials. Research in both animals and humans shows that MK-677 may have important benefits for appetite, body composition, muscle strength, cardiac health, and neurologic function. Studies have shown that MK-677 may have particular benefit in promoting vascular health and helping to stave off some of the most prevalent diseases in industrial societies (e.g. atherosclerosis, Alzheimer’s disease, etc.). MK-677 also appears to have profound and beneficial effects on sleep quality. It may not only provide an effect means of improving sleep quality and probing the finer details of the sleep cycle, but it’s ability to improve sleep may help to explain some of its neurological benefits. More research needs to take place in this arena, but MK-677 shows exceptionally promising benefits in improving sleep quality. Interestingly, research seems to suggest that the greatest benefits of MK-667 are derived when it is taken for long periods of time as a preventative. Research may help to shed light on this particular phenomenon and set the stage for MK-677 and similar developments to act as preventatives for some of the most devastating diseases associated with age.

기사 저자

위의 문헌은 M.D. E. Logan 박사가 연구, 편집 및 조직했습니다. E. Logan 박사는 박사 학위를 취득했습니다.사례 서부 예비 대학교 의과 대학그리고 B.S. 분자 생물학에서.

과학 저널 저자

Ralf M Nass, MD독일 보츠 대학교 (University of Bochum)의 의과 대학에 다니고 독일 뮌헨 대학교 (University of Munich)와 버지니아 대학 (University of Virginia) (신경 내분비학)에서 거주 및 친교를 마쳤습니다. 그는 당뇨병 (입원 환자 및 외래 환자), 갑상선 질환, 뇌하수체 질환 및 PCOS에 중점을 둔 내분비학을 전문으로했습니다. 직장 밖에서의 인생에서 나는 야외, 하이킹 및 스포츠를 즐깁니다.

Ralf M Nass, MD는 VIP의 연구 개발에 관여하는 주요 과학자 중 한 명으로 언급되고 있습니다. 이 의사/과학자가 어떤 이유로 든이 제품의 구매, 판매 또는 사용을지지하거나 옹호하는 것은 아닙니다. 묵시적 또는 다른 방식으로 제휴 나 관계가 없습니다.
펩티드 전문가그리고이 의사. 의사를 인용하는 목적은이 펩티드를 연구하는 과학자들이 수행 한 철저한 연구 개발 노력을 인정, 인식 및 인정하는 것입니다. Barbara B. Kahn은 참조 인용에 따라 [2]와 [6]에 나와 있습니다.

참조 인용

    “CAS Common Chemistry.” https://commonchemistry.cas.org/detail?cas_rn=159634-47-6 (accessed Apr. 15, 2021). R. Nass et al., “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial,” Ann. Intern. Med., vol. 149, no. 9, pp. 601–611, Nov. 2008, doi: 10.7326/0003-4819-149-9-200811040-00003. M. G. Murphy et al., “MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism,” J. Clin. Endocrinol. Metab., vol. 83, no. 2, pp. 320–325, Feb. 1998, doi: 10.1210/jcem.83.2.4551. D. M. Ney, “Effects of insulin-like growth factor-I and growth hormone in models of parenteral nutrition,” JPEN J. Parenter. Enteral Nutr., vol. 23, no. 6 Suppl, pp. S184-189, Dec. 1999, doi: 10.1177/014860719902300603. J. T. Sigalos and A. W. Pastuszak, “The Safety and Efficacy of Growth Hormone Secretagogues,” Sex. Med. Rev., vol. 6, no. 1, pp. 45–53, Jan. 2018, doi: 10.1016/j.sxmr.2017.02.004. J. Svensson et al., “Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males,” J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res., vol. 13, no. 7, pp. 1158–1166, Jul. 1998, doi: 10.1359/jbmr.1998.13.7.1158. M. G. Murphy et al., “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group,” J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res., vol. 14, no. 7, pp. 1182–1188, Jul. 1999, doi: 10.1359/jbmr.1999.14.7.1182. A. Adunsky et al., “MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study,” Arch. Gerontol. Geriatr., vol. 53, no. 2, pp. 183–189, Oct. 2011, doi: 10.1016/j.archger.2010.10.004. J. J. Sevigny et al., “Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial,” Neurology, vol. 71, no. 21, pp. 1702–1708, Nov. 2008, doi: 10.1212/01.wnl.0000335163.88054.e7. Y.-O. Jeong et al., “MK-0677, a Ghrelin Agonist, Alleviates Amyloid Beta-Related Pathology in 5XFAD Mice, an Animal Model of Alzheimer’s Disease,” Int. J. Mol. Sci., vol. 19, no. 6, Jun. 2018, doi: 10.3390/ijms19061800. G. Copinschi et al., “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man,” Neuroendocrinology, vol. 66, no. 4, Art. no. 4, Oct. 1997. T. Thum et al., “Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1,” Circ. Res., vol. 100, no. 3, pp. 434–443, Feb. 2007, doi: 10.1161/01.RES.0000257912.78915.af. J. K. Devin et al., “Low-dose growth hormone administration mobilizes endothelial progenitor cells in healthy adults,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 18, no. 3, pp. 253–263, Jun. 2008, doi: 10.1016/j.ghir.2007.11.001. T. Thum et al., “Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I,” J. Clin. Endocrinol. Metab., vol. 92, no. 11, pp. 4172–4179, Nov. 2007, doi: 10.1210/jc.2007-0922.
이 웹 사이트에 제공된 모든 기사 및 제품 정보는 정보 및 교육 목적으로 만 사용됩니다.이 웹 사이트에서 제공되는 제품은 투명한 연구를 위해 제공됩니다. 내역 연구 (라틴어 : 유리)는 신체 외부에서 수행됩니다. 이 제품은 의약품이나 약물이 아니며 FDA에 의해 의학적 상태, 질병 또는 질병을 예방, 치료 또는 치료하기 위해 승인되지 않았습니다. 인간이나 동물에 어떤 종류의 신체적으로 소개되는 것은 법에 의해 엄격히 금지되어 있습니다.

요청 요청

우리에 대해

Peptidegurus는 미국에서 만든 연구 펩티드의 주요 공급 업체로 경쟁력있는 가격으로 최고 품질의 제품을 제공합니다. 우수성 및 고객 서비스에 중점을 두어 글로벌 배송으로 안전하고 편리한 주문 프로세스를 보장합니다.

제품

견적을 요청하십시오

  • 펩티드 전문가
    • info@peptidegurus.com
  • 글렌 데일, 그것은 미국입니다

    • 연락하다

    요청 요청